Contact Us | Careers

Corium Inc.
  • About Us
    • Leadership
    • Board of Directors
    • Our Mission
    • CVR Holders
  • Pipeline & Products
    • Alzheimer’s Disease
    • Contraception
  • Technology
    • R&D Capabilities
    • Corplex
    • MicroCor
  • Partnering
  • Manufacturing
  • News Releases
  • About Us
    • Leadership
    • Board of Directors
    • Our Mission
    • CVR Holders
  • Pipeline & Products
    • Alzheimer’s Disease
    • Contraception
  • Technology
    • R&D Capabilities
    • Corplex
    • MicroCor
  • Partnering
  • Manufacturing
  • News Releases

News Releases

May 24, 2018

By coriumi1-ca -

Corium to Present at the Jefferies 2018 Global Healthcare Conference
MENLO PARK, Calif. , May 24, 2018 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple , Corium’s President and…

May 14, 2018

By coriumi1-ca -

Corium Reports Second Quarter Fiscal 2018 Finaical Results and Corporate Highlights
MENLO PARK, Calif. , May 14, 2018 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the second…

May 8, 2018

By coriumi1-ca -

Corium to Report Second Quarter Fiscal 2018 Financial Results on Monday, May 14, 2018
MENLO PARK, Calif. , May 08, 2018 (GLOBE NEWSWIRE) — Corium International, Inc. (NASDAQ:CORI) today announced that it will report financial results for the second quarter ended March 31, 2018 on Monday, May 14, 2018 after the close of the U.S. financial markets. Corium will host a conference call…

March 19, 2018

By coriumi1-ca -

Corium to Present at the 17th Annual Needham Healthcare Conference
MENLO PARK, Calif. , March 19, 2018 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple , Corium’s President and…

March 1, 2018

By coriumi1-ca -

Corium Prices Offering of $100 Million of 5% Convertible Senior Notes
MENLO PARK, Calif. , March 01, 2018 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced the pricing of its offering of $100,000,000…

Page 3 of 20‹12345›»
See all News

News Archive

  • Home
  • About Us
  • Pipeline & Products
  • Technology
  • Partnering
  • Manufacturing
  • News Releases
  • Contact Us
  • Terms of Use
  • Privacy Policy








© 2019 Corium Inc. All rights reserved.